180-day exclusivity rule on hold
Executive Summary
"With the recent court decisions, not only already acted upon but pending, as well as the McCain/Schumer bill, things are very, very open to changing," OGD's Davis said. FDA's "180-day final rule for all intents and purposes right now is on hold." McCain/Schumer would allow rolling exclusivity (1"The Pink Sheet" May 7, p. 8)
You may also be interested in...
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials